CO6251289A2 - Compuestos de bencesulfonamida apropiadas pata tratar trastornos que correspondan a la modulacion del receptor de dopamina d3 - Google Patents

Compuestos de bencesulfonamida apropiadas pata tratar trastornos que correspondan a la modulacion del receptor de dopamina d3

Info

Publication number
CO6251289A2
CO6251289A2 CO09148550A CO09148550A CO6251289A2 CO 6251289 A2 CO6251289 A2 CO 6251289A2 CO 09148550 A CO09148550 A CO 09148550A CO 09148550 A CO09148550 A CO 09148550A CO 6251289 A2 CO6251289 A2 CO 6251289A2
Authority
CO
Colombia
Prior art keywords
compound according
hydrogen
bencesulfonamide
dopamine
correspond
Prior art date
Application number
CO09148550A
Other languages
English (en)
Inventor
Sean C Turner
Andreas Haupt
Wilfried Braje
Udo Lange
Karla Drescher
Liliane Unger
Ana Lucia Jonge-Relo
Anton Bespalov
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of CO6251289A2 publication Critical patent/CO6251289A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached

Abstract

1.- Un compuesto N-(6-piperazin-1-ilpiridin-3-il) bencensulfonamida de la fórmula Idonde R1 se selecciona entre el grupo que consiste en hidrógeno, C1-C3 alquilo lineal y C1-C3 alquilo lineal fluorado; R2 es hidrógeno o metilo; R3 se selecciona entre el grupo que consiste en hidrógeno, halógeno, C1-C2-alquilo, C1-C2-alquilo fluorado, C1-C2-alcoxi y C1-C2-alcoxi fluorado, R4 es C1-C2-alquilo o C1-C2-alquilo fluorado; n es 0,1 o 2;y las sales fisiológicamente toleradas de este compuesto y los N-óxidos del mismo. 2.- El compuesto de acuerdo con la reivindicación 1, donde R1 es hidrógeno. 3.- El compuesto de acuerdo con las reivindicaciones 1 o 2, donde R2 es metilo.4.- El compuesto de acuerdo con la reivindicación 3, donde el átomo de carbono que lleva a R2 tiene configuración S.5.- El compuesto de acuerdo con la reivindicación 3, donde el átomo de carbono que lleva a R2 tiene configuración R.6.- El compuesto de acuerdo con las reivindicaciones 1 o 2, donde R2 es hidrógeno. 7.- El compuesto de acuerdo con cualquiera de las reivindicaciones precedentes, donde R3 es metilo. 8.- El compuesto de acuerdo con cualquiera de las reivindicaciones precedentes, donde R4 es metilo. 9.- El compuesto de acuerdo con la reivindicación 8, donde el átomo de carbono que lleva a R4 tiene configuración S.10.- El compuesto de acuerdo con la reivindicación 8, donde el átomo de carbono que lleva a R4 tiene configuración R.11.- El compuesto de acuerdo con cualquiera de las reivindicaciones precedentes, donde n es 1.12.- El compuesto de acuerdo con cualquiera de las reivindicaciones precedentes, donde n es 2.
CO09148550A 2007-10-31 2009-12-29 Compuestos de bencesulfonamida apropiadas pata tratar trastornos que correspondan a la modulacion del receptor de dopamina d3 CO6251289A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119788 2007-10-31

Publications (1)

Publication Number Publication Date
CO6251289A2 true CO6251289A2 (es) 2011-02-21

Family

ID=40280677

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09148550A CO6251289A2 (es) 2007-10-31 2009-12-29 Compuestos de bencesulfonamida apropiadas pata tratar trastornos que correspondan a la modulacion del receptor de dopamina d3

Country Status (24)

Country Link
US (4) US20100210664A1 (es)
EP (1) EP2203426B9 (es)
JP (1) JP5680416B2 (es)
KR (1) KR20100080500A (es)
CN (1) CN101687802B (es)
AT (1) ATE522505T1 (es)
AU (1) AU2008320875B2 (es)
BR (1) BRPI0812978A2 (es)
CA (1) CA2690976A1 (es)
CO (1) CO6251289A2 (es)
CR (1) CR11188A (es)
DO (1) DOP2009000295A (es)
EC (1) ECSP099832A (es)
ES (1) ES2371308T3 (es)
GT (1) GT200900332A (es)
IL (1) IL202814A (es)
MX (1) MX2009014236A (es)
MY (1) MY153300A (es)
NZ (1) NZ582095A (es)
RU (1) RU2485103C2 (es)
TW (1) TWI469782B (es)
UA (1) UA99628C2 (es)
WO (1) WO2009056600A1 (es)
ZA (1) ZA200909171B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2948192T3 (es) 2013-06-27 2023-09-01 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina D1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds

Also Published As

Publication number Publication date
ATE522505T1 (de) 2011-09-15
EP2203426B9 (en) 2013-02-13
CN101687802A (zh) 2010-03-31
EP2203426B1 (en) 2011-08-31
JP2011500771A (ja) 2011-01-06
TWI469782B (zh) 2015-01-21
ES2371308T3 (es) 2011-12-29
IL202814A0 (en) 2010-06-30
ECSP099832A (es) 2010-01-29
NZ582095A (en) 2012-08-31
UA99628C2 (ru) 2012-09-10
US20100210664A1 (en) 2010-08-19
CN101687802B (zh) 2014-02-26
EP2203426A1 (en) 2010-07-07
MX2009014236A (es) 2010-05-03
RU2010121830A (ru) 2011-12-10
MY153300A (en) 2015-01-29
TW200932234A (en) 2009-08-01
CR11188A (es) 2010-05-27
US20140200224A1 (en) 2014-07-17
AU2008320875B2 (en) 2013-08-01
JP5680416B2 (ja) 2015-03-04
GT200900332A (es) 2012-04-03
AU2008320875A1 (en) 2009-05-07
KR20100080500A (ko) 2010-07-08
CA2690976A1 (en) 2009-05-07
US20110319421A1 (en) 2011-12-29
WO2009056600A1 (en) 2009-05-07
IL202814A (en) 2015-05-31
BRPI0812978A2 (pt) 2014-12-16
ZA200909171B (en) 2012-05-30
DOP2009000295A (es) 2010-01-31
RU2485103C2 (ru) 2013-06-20
US20150175570A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
CO6210751A2 (es) Derivados de indolinona y procedimiento para su fabricacion
AR061739A1 (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201170096A1 (ru) Замещенные производные пиримидона
CU20100021A7 (es) Derivado de oxopirazina y herbicida
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
PE20121048A1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
PE20130187A1 (es) Bis(difluorometil) pirazoles como fungicidas
CO6241076A2 (es) Compuestos de benzamida y aplicaciones de los mismos
DOP2011000061A (es) Compuestos de pirrol
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
UY32146A (es) Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
UY29690A1 (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
DOP2006000076A (es) Derivados de ciclopentapiridina y tetrahidroquinolina
AR067691A1 (es) Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas.
CY1111428T1 (el) Μεθοδος για τη συνθεση της 5-(μεθυλ-1η-ιμιδαζολ-1-υλο)-3-(τριφθορομεθυλο)-βενζολαμινης
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
CU20090048A7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR054341A1 (es) Combinaciones sinergicas de compuestos activos fungicidas
AR061806A1 (es) Derivados de alquilpiridazina como inhibidores de 11b-hsd1 (t2d)
CO5720994A2 (es) Derivados sustituidos del pirrol

Legal Events

Date Code Title Description
FC Application refused